JUST IN [Thread] 1. Early findings from 2 SA studies suggest #Omicron has a much higher rate of asymptomatic "carriage" (#COVID19 without symptoms) than previous variants and this is likely an important reason why the variant spreads so fast.
Preprint: bit.ly/3q8NykS
2. Which studies are findings based on? 1. Ubuntu: A sub-Saharan #Africa study that measures the effectiveness of #Moderna's #COVID19 jab in #HIV+ people (all initial sites in SA) 2. A sub-study of #Sisonke, conducted among SA #HealthWorkers, that measures #JnJ's effectiveness
3. Neither of the studies = designed 2 look @ asymptomatic infections specifically, rather 2 measure breakthrough infections, immunogenicity + effectiveness of jabs in HIV+ and other groups, but they do give useful info on how #Omicron's spread differs from other variants.
4. What did the Ubuntu study show?
- Study period: 2 - 17 Dec
- 31% of unvaccinated volunteers had #COVID19 without symptoms (71/230 participants)
- This is in sharp contrast with pre-#Omicron studies: During ancestral, Beta + Delta variants rates = 1%-2.6%, so 7-12x lower
5. What did #Sisonke find?
- Study period: mid-November to Dec 7
- 2.6% of vaccinated (with #JnJ) volunteers had #COVID19 without symptoms during the Beta and Delta outbreaks. With #Omicron this rose to 16% (91/577 participants)
6. How did researchers know asymptomatic carriers were infected with #Omicron? 1. Proportions of the samples were sequenced 2. They looked at PCR test results (if a certain gene, called an S gene, was not picked up, it indicated it was Omicron (this is known as S gene dropout)
7. What do the (early) findings mean? 1. #Omicron infection possibly results in a higher % of people with asymptomatic #COVID19 than other variants 2. This likely plays an NB role in its fast spread — even among populations with high prior rates of #SARSCOV2 infection (like SA)
8. Many of the asymptomatic carriers in the studies had high nasal viral titers (so a lot of virus) — suggesting that sub-clinical carriage (so disease without symptoms) could be a major reason why #Omicron is spreading so fast globally.
🧵1. BREAKING: The peer-reviewed results of the study of a 6-monthly jab, #lenacapavir, in which not a single of the 2134 women between 16-25 years who received the jab contracted #HIV, were released at #Aids2024.
2. Women often find it hard to adhere to daily #oralPrEP. In the Purpose 1 trial, 91.5% of women returned on time for their next #lenacapavir jab at 26 weeks and 92.8% at week 52.
3. Only 4 women out of 2134 (0.2%) who received #lenacapavir dropped out of the trial because of injection-site reactions.
[Thread] 12 things to know about the the proportion of pregnant women infected with #HIV from SA’s latest antenatal HIV survey. The survey is conducted by the @nicd_sa.
(Analysis of our 95-95-95 goals in my next thread later in Jan).
1/12
2. What is the antenatal #HIV survey?
1. It measures the % of HIV+ pregnant women between the ages of 15 + 49. 2. Only women using state pregnancy clinics take part. 3. The survey has been conducted each year between 1990-2015, then in 2017, 2019 +2022.
3. How many pregnant women between 15-49’s blood was tested for #HIV? 37 828 out of 40 542 collected samples.
- 37 7171 = Black African women
- 37 541 didn’t live with the dad of their child
- 35,635 of dads were 5 years+ older than moms (this makes them more likely to get HIV)
JUST IN [Thread]:
1.@healthza's Lesley Broomberg:
An extra #COVID19 booster jab for people of 18+ in SA will become available towards the end of JANUARY
- People of 50+ qualify for a 5th dose
- People of 18+ qualify for a 4th dose
2. Lesley Broomberg: Can you mix and match with additional boosters? Yes. You can choose whether you want a #JnJ or #Pfizer booster.
3. Lesley Broomberg:
Will teens of 12-17 qualify for boosters? Not at this stage. Why not? The #VMAC = not recommended booster doses for 12-17, based on an understanding that the protection provided by 2 #Pfizer doses = adequate, as 12-17 = @ low risk of severe #COVID19 illness
[Thread] #JoePhaahla:
- Genomic surveillance Network reported the detection of the new subvariant XBB.1.5 in SA of a sample of a patient tested on 22 Dec
- Details of the patient = not known, it was a random sample taken for testing
- XBB.1.5 = also common in US
2. XBB.1.5 = common in US
#JoePhaahla:
- 97%+ of #COVID19 cases worldwide = still #Omicron
- XBB.1.5 cases = no major change in hospitalisations or deaths
- Immunity of SAs (vax and natural immunity) = still strong, so that is why we haven't seen much change in terms of hospital admissions/deaths
Which APIs will Aspen use?
India's Serum Institute's
2. Why is it NB that an African company makes these jabs?
#Africa imports almost all its jabs. #COVID19 showed us this results in Africa being last in line to get vaccines during pandemics. The grant to Aspen is 1 of the 1st steps to change that.
3. What's the goal?
By 2040, the African Union wants #Africa to make 60% of the jabs the continent uses.
Why?
So that Africa is better equipped 2 respond 2 outbreaks (by developing the ability to make jabs + have technology in place to also make new jabs during pandemics).
🧵1. BREAKING: @SAHPRA1 has confirmed the registration of the #HIV prevention jab, #CABLA in South Africa. On Thursday, #ViiVHealthcare issued their statement.
2. Who can use the jab? @SAHPRA1 didn't specify restrictions for use in their statement, only that it is "a highly effective option for people at substantial risk of #HIV infection."
3. How does the jab work? It uses an #ARV called cabotegravir that prevents #HIV from replicating and entering someone’s cells. It’s taken every two months. Read my latest story for more. bit.ly/3ER7ejq